<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00738790</url>
  </required_header>
  <id_info>
    <org_study_id>PGBRJG0108</org_study_id>
    <secondary_id>KBN0655/P05/2005/28</secondary_id>
    <nct_id>NCT00738790</nct_id>
  </id_info>
  <brief_title>Preoperative Radiotherapy and Local Excision in Rectal Cancer</brief_title>
  <official_title>The Randomised Study of Preoperative Radiotherapy and Local Excision for Radiosensitive Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polish Colorectal Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maria Sklodowska-Curie Institute - Oncology Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Poznan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Lublin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Polish Colorectal Cancer Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to the current opinion, local excision in rectal cancer should be limited to
      selected T1N0 tumours. The investigators addressed the question whether preoperative
      radio(chemo)therapy can expand the use of this procedure for more advanced cancers. The
      rationale of preoperative radiotherapy is eradication of mesorectal subclinical disease.
      Besides, there is a correlation between radiosensitivity of rectal cancers and low cancer
      aggressiveness. For this reason, conversion to abdominal surgery is needed in patients with
      radioresistant tumour. The investigators aim to compare the short-course radiotherapy
      schedule with the chemoradiation in order to determine an optimal scheme. The study
      hypothesis is that the chemoradiation assures 25% more patients who do not require conversion
      to an open surgery. In addition, the aim is to asses safety and efficiency of preoperative
      radiotherapy and local excision for radiosensitive rectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Local excision must involve all tissue invaded on pretreatment examination. For this reason,
      4-5 tatoos of mucosa at the tumour border should be performed before the onset of treatment.
      Next, the long-course radiochemotherapy or short-course radiotherapy is randomly allocated.
      After 6 weeks interval, the full thickness local excision should be carried out with 1 cm
      margin. Patients with good pathological response (complete response or downstaging to ypT1
      disease)are followed up. Conversion to open surgery is offered to patients with poor
      pathological response (ypT2-3 or positive margin). Close follow-up is carried out in order to
      detect an early local recurrence either in a bowel wall or in mesorectal lymph nodes. Rescue
      surgery is offered in patients with local recurrence.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2003</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of patients with downstaging after radiotherapy to pathological complete response or ypT1 disease with negative margins.</measure>
    <time_frame>Surrogate endpoint available immediatly after surgery.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of local control, overall survival and disease-free survival and toxicity.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative radiotherapy with five fractions of 5 Gy during one week and boost 4 Gy after 1 week interval, total dose 29 Gy; after 6 weeks full-thickness local excision</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiochemotherapy with 28 fractions of 1,8 Gy plus boost 5,4 Gy in 3 fractions
+ simultaneous bolus 5-Fluorouracil and leucovorin; after 6 weeks full-thickness local excision</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Short course of radiotherapy</intervention_name>
    <description>5 x 5 Gy plus boost 4 Gy</description>
    <arm_group_label>1</arm_group_label>
    <other_name>short radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiochemotherapy</intervention_name>
    <description>28 x 1,8Gy plus boost 3 x 1,8 Gy with three 2-days cycles of chemotherapy during weeks 1, 3 and 5 of irradiation (the each cycle consisted of leukovorin 20 mg/m2 per day and 10-20 minutes later of 5-fluorouracil 400 mg/m2 per day, both administrated as rapid intravenous infusion)</description>
    <arm_group_label>2</arm_group_label>
    <other_name>chemoradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven good or moderately differentiated adenocarcinoma of rectum

          -  Extraperitoneal tumour (&lt; 3-4 cm; unfavourable cT1 or cT2-3; N0)

          -  No evidence of distant metastases on chest X-ray and abdominal CT or sonography

          -  Signed by patient written informed consent

        Exclusion Criteria:

          -  Poorly differentiated pathology (G3)

          -  Patients unfit for chemotherapy

          -  No agreement for randomisation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Krzysztof Bujko, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roentgena 5, 02-781 Warsaw, Poland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wojciech Michalski, M. S.</last_name>
    <phone>+48226433909</phone>
    <email>W.Michalski@coi.waw.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>M. Sklodowska-Curie Memorial Cancer Centre</name>
      <address>
        <city>Warsaw</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krzysztof Bujko, Prof.</last_name>
      <phone>+48226439287</phone>
      <email>bujko@coi.waw.pl</email>
    </contact>
    <investigator>
      <last_name>Krzysztof Bujko, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Bujko K, Sopylo R, Kepka L. Local excision after radio(chemo)therapy for rectal cancer: is it safe? Clin Oncol (R Coll Radiol). 2007 Nov;19(9):693-700. Epub 2007 Sep 4. Review.</citation>
    <PMID>17766096</PMID>
  </reference>
  <reference>
    <citation>Bujko K, Richter P, Kołodziejczyk M, Nowacki MP, Kulig J, Popiela T, Gach T, Oledzki J, Sopyło R, Meissner W, Wierzbicki R, Polkowski W, Kowalska T, Stryczyńska G, Paprota K; Polish Colorectal Study Group. Preoperative radiotherapy and local excision of rectal cancer with immediate radical re-operation for poor responders. Radiother Oncol. 2009 Aug;92(2):195-201. doi: 10.1016/j.radonc.2009.02.013. Epub 2009 Mar 16.</citation>
    <PMID>19297050</PMID>
  </reference>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2008</study_first_submitted>
  <study_first_submitted_qc>August 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2008</study_first_posted>
  <last_update_submitted>April 14, 2010</last_update_submitted>
  <last_update_submitted_qc>April 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Marek P. Nowacki</name_title>
    <organization>Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology in Warsaw</organization>
  </responsible_party>
  <keyword>rectal cancer</keyword>
  <keyword>preoperative radiotherapy and local excision</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

